Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600267'
s EV-to-FCF Range Over the Past 10 Years
Min: -281.73 Med: 9.24 Max: 416.02
Current: 8.04
During the past 13 years, the highest EV-to-FCF of Zhejiang Hisun Pharmaceutical Co was 416.02. The lowest was -281.73. And the median was 9.24.
SHSE:600267's EV-to-FCF is ranked better than 83.13% of 569
companies
in the Drug Manufacturers industry
Industry Median: 20.47
vs SHSE:600267: 8.04
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Hisun Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Hisun Pharmaceutical Co's share price for today is ¥11.72.
Zhejiang Hisun Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Hisun Pharmaceutical Co EV-to-FCF Related Terms
Zhejiang Hisun Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Hisun Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's EV-to-FCF falls into.
Zhejiang Hisun Pharmaceutical Co's current Enterprise Value is ¥14,611 Mil.
Zhejiang Hisun Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,764 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a EV-to-FCF of 8.28 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. This is 10% below median its historical median of 9.24. According to the industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #96 out of 569 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is Zhejiang Hisun Pharmaceutical Co's EV-to-FCF too high?
Zhejiang Hisun Pharmaceutical Co's current EV-to-FCF of 8.28 is 10% below median its 10-year median of 9.24. The Drug Manufacturers industry median EV-to-FCF is 20.47. Zhejiang Hisun Pharmaceutical Co's value of 8.28 is 59.6% below this industry median. Based on the distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #96 out of 569 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Hisun Pharmaceutical Co ranks #96 out of 569 companies for EV-to-FCF. This places Zhejiang Hisun Pharmaceutical Co in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.47. Zhejiang Hisun Pharmaceutical Co's value of 8.28 is 59.6% below this benchmark. While the company's 10-year median is 9.24 vs. the industry median of 20.47, Zhejiang Hisun Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.47, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Hisun Pharmaceutical Co's current EV-to-FCF of 8.28 is 59.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Hisun Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Hisun Pharmaceutical Co's current EV-to-FCF is 8.28, which is 10% below median its own 10-year median of 9.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.85, compared to a current price of ¥11.72 — trading 32.4% above its estimated fair value. The current EV-to-FCF is 8.28, which is 10% below median its 10-year median of 9.24 and 59.6% below the Drug Manufacturers industry median of 20.47. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current EV-to-FCF is 8.28 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
EV-to-FCF: 8.28 (10% below median its 10-year median of 9.24)
GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
Industry Position: 59.6% below the Drug Manufacturers median (#96 of 569)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
